NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $2.15 -0.16 (-6.93%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BCLI alerts:Sign Up Key Stats Today's Range$2.11▼$2.3950-Day Range$0.22▼$3.2552-Week Range$2.01▼$11.89Volume103,363 shsAverage Volume49,811 shsMarket Capitalization$150.67 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingBuy Company OverviewBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Read More… [SHOCKING] Crypto Document Leak… (Ad)Imagine if you could go back to 2009 and buy Bitcoin at $0.01. Or jump to 2015 and grab Ethereum at $0.75. We've created the next best thing: It's called "Crypto Revolution," and it's not just a book… it's your potential ticket to financial time travel.Download your digital copy of "Crypto Revolution" now (limited-time offer). Brainstorm Cell Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreBCLI MarketRank™: Brainstorm Cell Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 409th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBrainstorm Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Brainstorm Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.19) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Brainstorm Cell Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.00% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.66 Percentage of Shares Shorted2.00% of the outstanding shares of Brainstorm Cell Therapeutics have been sold short.Short Interest Ratio / Days to CoverBrainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainstorm Cell Therapeutics has recently increased by 8.53%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.33 News SentimentBrainstorm Cell Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have sold 335.77% more of their company's stock than they have bought. Specifically, they have bought $5,060.00 in company stock and sold $22,050.00 in company stock.Percentage Held by InsidersOnly 5.45% of the stock of Brainstorm Cell Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.Read more about Brainstorm Cell Therapeutics' insider trading history. Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Stock News HeadlinesBrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual SummitOctober 7 at 7:00 AM | prnewswire.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.comOctober 2, 2024 | americanbankingnews.comMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.October 8, 2024 | Paradigm Press (Ad)Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Large Growth in Short InterestSeptember 30, 2024 | americanbankingnews.comBrainstorm Cell (NASDAQ:BCLI) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comStrong Buy Recommendation for Brainstorm Cell Therapeutics Amid Positive Clinical Developments and Strategic FDA MilestonesSeptember 26, 2024 | markets.businessinsider.comBrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS MeetingSeptember 24, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comSee More Headlines BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $0.2730 at the beginning of the year. Since then, BCLI stock has increased by 687.5% and is now trading at $2.15. View the best growth stocks for 2024 here. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting analysts' consensus estimates of ($0.04). When did Brainstorm Cell Therapeutics' stock split? Brainstorm Cell Therapeutics's stock reverse split on Tuesday, October 1st 2024. The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX). Company Calendar Last Earnings8/14/2024Today10/08/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCLI CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside-10.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-373.68% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-27.88Miscellaneous Outstanding Shares70,081,000Free Float66,262,000Market Cap$156.28 million OptionableOptionable Beta0.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BCLI) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
